NPI 1831274026: Open Payments
NPI 1831274026. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$274 in 17 payments from 4 companies in 2025. Trend: 2023 $324 · 2024 $284 · 2025 $274
Food & beverage: $274
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 11 | $148 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Janssen Pharmaceuticals, Inc | 2 | $45 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
Products named: ARISTADA, UZEDY, INVEGA SUSTENNA, ERZOFRI EXTENDED-RELEASE.
